Merck & Co Inc

NYSE:MRK   3:59:59 PM EDT
81.36
+0.04 (+0.05%)
: $81.10 -0.26 (-0.32%)
Products

FDA Approves Merck’s KEYTRUDA (Pembrolizumab) As Adjuvant Treatment For Adult And Pediatric Patients

Published: 12/03/2021 23:27 GMT
Merck & Co Inc (MRK) - FDA Approves Merck’s Keytruda® (pembrolizumab) As Adjuvant Treatment for Adult and Pediatric (≥12 Years of Age) Patients With Stage Iib Or Iic Melanoma Following Complete Resection.